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Abstract
Introduction: Infection with the bacteria carpamenease-producing Klebsiella pneumonia (PKP) represents 
a significant cause of mortality in hospitalized patients. These multidrug-resistant bacteria are resistant 
to currently used antibiotics as a result of carbapenemase production. Dual-carbapenem therapy (DCT) 
has been proposed as a valid therapeutic option, this therapy combines two carbapenem antibiotics, 
with one acting as a suicide inhibitor allowing the subsequent carbapenem to exert a bactericidal effect. 
Aim: The aim of this meta-analysis was to determine if DCT had a significant effect on mortality rate and 
microbiological cure rate in patients diagnosed with carbapenemase-PKP infections in comparison to 
standard antibiotic therapies. Methods: The search terms “(dual OR double) carbapenem (therapy OR 
treatment) AND Klebsiella pneumoniae” were used to search databases and inclusion and exclusion criteria 
were applied to retrieved papers, a total of seven studies were identified for inclusion in the meta-analysis. 
The quality of included studies was assessed using the cochrane tool for risk of bias assessment and funnel 
plots were produced to determine the influence of publication bias. A random effects model was used to 
assess the outcomes; mortality rate and microbiological cure rate. Results: DCT had a time dependent 
effect on patient mortality rates. DCT significantly lowered mortality rates in patients in comparison to 
standard antibiotic therapy, especially in comparison to monotherapy treatment regimens. In addition, DCT 
significantly improved microbiological cure rate in patients when compared to standard antibiotic treatment 
regimens. Demonstrating the possible clinical applications of a dual carbapenem antibiotic regimen in the 
treatment of carbapenemase-PKP infections.
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Introduction
Carbapenemase-producing Klebsiella pneumoniae 
(PKP) infection and dual carbapenem therapy (DCT)
K. pneumoniae is one of the most common 
Gram-negative causes of nosocomial infection.[1] 
Carbapenem antibiotics are usually effective in the 
treatment of multidrug-resistant bacterial strains. 
For this reason, carbapenem antibiotics are usually 
the last line of defense to treat infections caused by 
K. pneumoniae. Recently, however, there has been 
a growing trend in the number of carbapenem-
resistant (CR)/PKP isolates. The increasing 
emergence of CRKP possesses a threat to health 
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globally and has been associated with increased 
health care costs, prolonged hospital stays, 
treatment failure, and increased mortality, thus the 
need for novel treatment strategies is evident.[1] In 
an effort to fight this multidrug-resistant bacterium a 
new treatment was put forward: Double DCT.[2] DCT 
utilizes a dual carbapenem antibiotic combination, 
the first carbapenem acts as a suicide inhibitor of 
the carbapenemase enzyme, allowing the second 
carbapenem to have a bactericidal effect.
K. pneumoniae: The emerging threat
K. pneumoniae isolates are associated with a variety 
of infections, including infections of the Urinary tract 
infection (UTIs) and infections of the bloodstream 
infection, frequently occurring at multiple body 
sites concurrently. Infections are also commonly 
associated with underlying comorbidities such as 
malignancy or previous organ transplantation.[1] 
CRKP are currently classified as critical according 
to the World Health Organization’s “priority list 
of pathogens for research and discovery of new 
antibiotics,” this list describes the bacteria which 
pose the greatest threat to health, as determined 
by; the fatality rate associated with their infection, 
the length of hospital stay, the rate of resistance to 
current antibiotics, and the availability of current 
treatments.[3] In addition, the European Centre 
for Disease Prevention and Control reported that 
currently more than one-third of K. pneumoniae 
isolates are resistant to at least one antibiotic.[4] 
Consequently, the need for an effective treatment 
of CPKP infections is vital.
Current treatments
The antibiotics colistin belonging to the polymyxin 
antibiotic class, tigecycline belonging to the 
glycylcycline antibiotic class, fosfomycin belonging 
to the phosphonic antibiotic class, and antibiotics 
form the aminoglycoside class, are currently used 
to treat infections caused by K. pneumoniae, 
either in mono- or combination-therapy, other 
example combination antibiotic strategies 
include ceftazidime-avibactam and meropenem-
vaborbactam.[5] However, limitations exist to 
the wide-spread use of these antibiotics. Due to 
increased usage, there is an increasing incidence of 
CPKP resistance to these antibiotics.[6] In addition, 
the potentially fatal adverse effect, dose-dependent 
nephrotoxicity is commonly associated with colistin 
administration.[7] Carbapenem antibiotics are used 
as a salvage treatment in K. pneumoniae infections, 
post failure of other antibiotics. The most common 
clinically administered carbapenem antibiotics 
include imipenem, meropenem, ertapenem, and 
doripenem. Recently developed carbapenems 
include tebipenem the first oral carbapenem, 
tomopenem whose bactericidal properties appear 
more potent than older carbapenems such as 
imipenem and meropenem as evidenced by in 
vitro and in vivo studies, and Sanfetrinem the first 
trinem carbapenem possessive of broad spectrum 
bactericidal activity.[8] Trinem carbapenems 
encompass tricyclic beta-lactams that possess a 
penicillin, cephalosporin, or carbapenem backbone. 
Due to the increasing resistance of K. pneumoniae 
isolates to these antibiotics, new treatment options 
are of vital importance.[9]
K. pneumoniae resistance mechanisms
CPKP are resistant to carbapenem antibiotics as a 
result of carbapenemase production. This enzyme is 
capable of hydrolyzing carbapenem antibiotics, thus 
rendering them inactive.[10] The carbapenemase 
enzyme is encoded for by extended spectrum 
beta-lactamase (KPC) (bla (KPC)) genes, evidencing 
this, Yan et al. found that 38.5% of CPKP isolates 
possessed bla-KPC carbapenemase-encoding-
genes.[11] In accordance, Logan and Weinstein, 
found similar results, noting that the minimum 
inhibitory concentration (MIC) of a carbapenem 
antibiotic was related to bla-KPC copy number.[12] 
Additional CPKP resistance mechanisms include 
the production of AmpC cephalorinase enzymes. 
OmpK 35/36 is porins present in the cell membrane 
of K. pneumoniae isolates; antibiotics exploit these 
porins to enter the bacterial cell and exert their 
bactericidal effect. Insertions or deletions in the 
OmpK 35/36 encoding genes, OmpK35/36, results 
in the inactivation of, or altered structure of, these 
porins, thus conferring additional resistance to 
CPKP isolates. The loss of these porins, particularly 
ompK 35, increases the MIC of the antibiotic, 
as reduced concentrations of antibiotic are able 
to enter the bacterial cell, generating increased 
resistance as a result of decreased phagocytosis. In 
addition, porin loss is able to significantly increase 
the production of the polysaccharide capsule 
surrounding the bacterium, which forms a physical 
barrier against the entry of antimicrobial agents as 
well as preventing the formation of the membrane 
attack complex. The absence of functional porins 
also acts to increase the lipopolysaccharide content 
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in the outer membrane of the CPKP bacteria, aiding 
in evasion from the host complement system and 
protecting against phagocytosis.[13,14]
DCT
In an effort to fight this multidrug-resistant 
bacterium a new treatment was put forward: DCT. 
Initially proposed by Bulik and Nicolau,[2] DCT has 
been shown to be an effective treatment for CPKP 
infections, when other antibiotic regimes have 
failed, even in cases when single carbapenems 
used in monotherapy have shown no bactericidal 
activity. DCT combines two carbapenem antibiotics, 
ertapenem with either meropenem or doripenem. 
Ertapenem is administered before the second 
carbapenem. Ertapenem dosage is lower than that 
of the second carbapenem. The carbapenemase 
enzyme produced by CPKP has a greater affinity 
for ertapenem in comparison to other carbapenem 
antibiotics, this is exploited in DCT.[2]
Importance of this study
Much of the research into the effectiveness of DCT is 
positive. DCT appears to be an effective alternative 
to monotherapy, lowering the mortality rate of 
patients, as well as improving both microbiological 
and clinical outcomes. However, the majority of 
these studies are case studies, or retrospective 
observational studies, which are characterized 
by small sample sizes. Meta-analyses regarding 
DCT and its effectiveness as a treatment for CPKP 
infections are currently lacking. The addition of 
a meta-analysis in this area would allow for the 
determination of the statistical significance in the 
effectiveness of DCT in treating infections caused 
by CPKP, allowing for the grouping together of 
existing data to generate an increased sample size, 
addressing the issues posed by the previous studies, 
leading to greater generalizability of findings. Such 
research could be used to inform clinical decisions 
regarding the use of DCT. The aim of this meta-
analysis is to determine if DCT has a significant 
effect on mortality rates in patients diagnosed 
with infections due to CPKP in comparison to 
monotherapy and alternate antibiotic combination 
regimens. An additional aim of this meta-analysis is 
to determine if there is a significant difference in 
the effect of DCT on mortality rates at different time 
points post initiation of treatment. Furthermore, 
this meta-analysis aims to determine if DCT 
significantly alters the microbiological cure rate in 




The search terms “(dual OR double) carbapenem 
(therapy OR treatment) AND Klebsiella pneumoniae” 
were used to search the following databases for 
relevant papers; PubMed, ScienceDirect, web of 
science, Wiley online library, Cochrane controlled 
trials register, and current controlled trials. In 
addition, the search terms were used to search the 
following conferences; Interscience Conference on 
Antimicrobial Agents and Chemotherapy 2011–2019, 
and the European Congress of Clinical Microbiology 
and Infectious Diseases 2014–2019. The reference 
sections of retrieved papers were searched for 
further relevant papers. The inclusion criteria applied 
were patients diagnosed with CR K. pneumoniae 
infection, patients in the experimental group must be 
receiving DCT, CR K. pneumoniae infections at all body 
sites were included, studies from all countries were 
included, all patients aged over 18 years of age were 
included in the study, only studies in which a control 
group was present were included, and only studies 
published pre 2020 were included in the study. The 
exclusion criteria applied were patients diagnosed 
with multiple infections caused by bacteria other 
than K. pneumoniae, animal studies were excluded 
from the study, studies lacking a control group 
were excluded from the study, studies published in 
languages other than English were excluded from the 
study, and any study published post January 1, 2020 
was excluded from the study.
Data extraction
The following data were extracted for each study; 
authors, year of publication, treatment received, 
sample size, number of deaths among patients 
receiving DCT, total number of patients receiving 
DCT, and either the number of deaths amongst 
patients receiving monotherapy and the total 
number of patients receiving monotherapy, or 
the number of deaths amongst patients receiving 
combination therapy and the total number of 
patients receiving combination therapy. The 
microbiological cure rates in patients treated with 
DCT and the microbiological cure rates in patients 
treated with standard antibiotic regimes were 
extracted from applicable studies.
Moody: DCT for the treatment of CPKP infections
Page 4 of 15  Journal of Medical Research and Innovation, Vol 5, Iss 1
Quality assessment of studies
To ensure study quality, all papers included in the 
meta-analysis were subject to peer-review. To 
ensure methodological quality, papers selected 
for inclusion were assessed for risk of bias in 
accordance with the Cochrane tool for assessing 
the risk of bias in non-randomized studies of 
interventions.[15,16] To be determined as having a 
low overall risk of bias, the study must be judged to 
be at low bias in all domains, and to be determined 
as having a moderate overall risk of bias the study 
must be judged to be at low or moderate risk of 
bias in all domains.[15,16] Only papers with a low or 
moderate risk of bias were included in the analysis. 
Funnel plots were produced to assess the impact of 
publication bias.
Definitions
DCT consisted of an antibiotic regimen containing two 
carbapenem antibiotics. Monotherapy consisted of a 
single active antibacterial agent. Combination therapy 
consisted of two or more active antibacterial agents 
used in combinations other than a dual carbapenem 
combination. Standard antibiotic therapy (SAT) 
consisted of appropriate antibiotic regimens, both 
monotherapy and combination therapies, exempting 
DCT. Mortality rate was determined as the number 
of deaths occurring in the population of patients 
with CPKP infections post initiation of treatment 
with DCT, monotherapy, or other antibiotic 
combination therapies at the following time points 
(where applicable for each study); 14 days mortality, 
28–30 day mortality, 60–90 days mortality, and the 
mortality rate at the latest follow-up time point 
within each study, termed the overall mortality rate. 
Microbiological cure was defined as cultures negative 
for the original pathogen, collected from the original 
site of infection, post antibacterial treatment.
Data analysis
The outcomes assessed were mortality rate and 
microbiological cure rate. Microbiological cure 
rates post-antibacterial treatment was assessed. 
Mortality rates post-initiation of treatment at 
the latest follow-up time point within each study 
was assessed. Mortality rates were then stratified 
according to the following time points; 14 days, 
28–30 days, and 60–90 days, post-initiation of 
treatment. A random effects model was used to 
assess these outcomes. The odds ratio (OR) and 
95% confidence interval (CI) were calculated for 
all included studies. The overall OR and 95% CI 
were calculated for each analysis. The overall 
effect (Z) and significance (p) were also calculated 
for each analysis. The I² statistic was used as the 
test of heterogeneity. The I² value was interpreted 
as follows: I² <50%: Low heterogeneity; I² = 
50–75%: Moderate heterogeneity; and I² ≥75%: 
High heterogeneity.[4] P < 0.05 was considered 
significant. The software Review Manager 




The search strategy of online databases identified 
599 studies; an additional study was identified 
through searching of conference databases. 600 
studies were screened for eligibility for inclusion 
based on title and abstract content, and the 
inclusion and exclusion criteria previously outlined 
were applied. Thirty duplicate studies were 
removed. Thirty studies were subject to full text 
review and the inclusion and exclusion criteria were 
applied. A total of seven studies were identified for 
inclusion in the meta-analysis.[17] Figure 1 illustrates 
the study selection.
Study characteristics
A total of seven studies were included in the meta-
analysis, with a total sample population of 1849 
patients included in the analysis, individual study 
population ranged from 36 to 595 patients. In 
total, 585 patients in this analysis received DCT, in 
comparison to 725 patients receiving monotherapy, 
and 539 patients receiving alternate antibiotic 
combination regimens. The studies included were 
published between 2015 and 2019. All included 
studies were retrospective, observational, and 
cohort studies. Sites of CPKP infections included UTI, 
blood stream, respiratory tract, intra-abdominal, 
and soft tissue. The DCT regimen most commonly 
administered in the included studies was ertapenem 
and meropenem at varying doses. Antibiotics 
administered in monotherapy regimens included 
colistin, gentamicin, tigecycline, aminoglycosides, 
meropenem, imipenem, cefepime, aztreonam, 
ceftazidime, and chloramphenicol. Antibiotics 
administered in combination regimens included 
meropenem plus another agent, rifampicin 
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plus another agent, colistin plus another agent, 
tigecycline plus another agent, and gentamicin plus 
another agent, as shown in Table 1.
Risk of bias assessment of included studies
The studies selected for inclusion were assessed for 
risk of bias and all included studies were determined 
Table 1: Characteristics of studies included in meta-analysis









Italy RTI, IAI, UTI, 
BSI, Multiple 
site infection
DCT (meropenem 6g 
every 8h, ertapenem 2g 
every 12h)
Monotherapy (Colistin 
9MIU every 12h, 
Gentamicin 5mg every 
24h, Tigecycline 100mg 
every 12h)
144
Cancelli et al. 2018 Single centre, 
observational 
study
Rome RTI, UTI, soft 
tissue
DCT (ertapenem 1g 



















Tumbarello et al. 2015 Retrospective 
cohort study
Italy BSI, RTI, IAI, 
UT










Tumbarello et al. 2015 Retrospective 
cohort study
Italy BSI, RTI, IAI, 
UT
DCT (meropenem and 
ertapenem)
Combination 
therapy (meropenem plus 
another agent, rifampicin 
plus another agent)
362







plus another agent, 
tigecycline plus another 
agent, gentamicin plus 
another agent)
595




USA BSI DCT (doripenem 2g every 
8h and ertapenem 1g 
every 24h 30 min prior to 
the doripenem infusion)
Combination 
therapy (colistin plus a 
carbapenem)
36
RTI: Respiratory tract infection, IAI: Intra-abdominal infection, UTI: Urinary tract infection, BSI: Bloodstream infection, DCT: Dual 
carbapenem therapy, g: Grams, mg: Milligrams, mIU: Milli-international units, h: Hours, De Pascale et al.,[18] Cancelli et al.,[19] 
Gutierrez-Gutierrez et al.,[20] Tumbarello et al.,[21] Onal et al.[22] Giannella et al.,[23] and Venugopalan et al.,[24]
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to have a moderate risk of bias, with the exception 
of the study conducted by Gutierrez-Gutierrez et al., 
2017[20] and that conducted by Venugopalan et al., 
2017[24] which were determined to have a low risk 
of bias. The studies conducted by De Pascale et al., 
2017[18] Cancelli et al., 2018,[19] Tumbarello et al., 
2015,[21] Onal et al., 2019,[22] and Gianella et al., 
2018[23] had a moderate risk of bias due to 
confounding, whereas the studies conducted by 
Gutierrez-Gutierrez et al., 2017[20] and Venugopalan 
et al., 2017[24] were determined to have a low risk of 
bias due to confounding. All studies included in the 
analysis were determined to have a low risk of bias in 
selection of participants into the study.[18-24] Similarly, 
all included studies were determined to have a low risk 
of bias due to deviations from intended interventions 
and in bias due to classification of interventions.[18-24] 
The study conducted by De Pascale et al., 2017,[18] 
was determined to have a moderate risk of bias 
due to missing data, all other included studies were 
determined to have a low risk of bias due to missing 
data.[19-24] In addition, all studies had low risk of bias in 
both measurements of outcomes and in selection of 
the reported result,[18-24] as shown in Table 2.
Mortality rates
Mortality rates in patients treated with DCT in 
comparison to monotherapy
The studies included in this analysis displayed low 
heterogeneity (I² = 0%). Patients receiving DCT 
had a lower overall mortality rate in comparison 
to patients receiving monotherapy (OR= 0.77, 
95% CI [0.50, 1.19]). However, the overall effect of 
DCT on mortality rates was non-significant (Z=1.19 
[P = 0.24]), as illustrated in Figure 2.
However, stratifying by time post-initiation of 
treatment revealed a significant effect. DCT 
significantly lowered the 28–30 days mortality rate 
in patients in comparison to patients treated with 
monotherapy regimes (OR = 0.44, 95% CI [0.17, 
1.10], Z = 1.76 [P = 0.08]). The studies included in 
this analysis displayed moderate heterogeneity 
(I² = 66%), as illustrated in Figure 3.
Mortality rates in patients treated with DCT in 
comparison to alternative antibiotic combinations
The studies included in the analysis displayed low 
heterogeneity (I² = 8%). Patients receiving DCT had 
a lower overall mortality rate in comparison to 
patients receiving alternate antibiotic combinations 
(OR = 0.71, 95% CI [0.45, 1.14]). However, the overall 
effect of DCT on mortality rate was non-significant 
(Z = 1.41 [P = 0.16]), as illustrated in Figure 4.
In contrast to the monotherapy subgroup, 
stratifying the mortality rate by time post-initiation 
of treatment for patients receiving combination 
therapy in comparison to those receiving DCT did 
not yield a significant effect (OR = 0.77, 95% CI [0.52, 
1.16], Z = 1.23 [P = 0.22]). The studies included in 
this analysis displayed low heterogeneity (I² = 0%), 


















Figure 1: PRISMA flow diagram illustrating the study selection process
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Figure 2: Overall mortality rates of CPKP infected patients treated with DCT in comparison to 
patients treated with a monotherapy antibiotic regimen. Data shown are number of deaths 
(events) and total number in group (total), data shown are odds ratio and 95% CI, events refer 
to mortality, CI-confidence interval, df- degrees of freedom, DCT- dual carbapenem therapy, 
experimental group received DCT treatment, control group received monotherapy, p<0.05 
is significant, De Pascale et al.,[18] Cancelli et al.,[19] Gutierrez-Gutierrez et al.,[20] Tumbarello 
et al.,[21] Onal et al.[22]
Figure 3: 28-30 mortality rate in patients treated with DCT in comparison to patients treated 
with monotherapy. Data shown are number of deaths (events) and total number in group 
(total), data shown is odds ratio and 95% CI, CI- confidence interval, df- degrees of freedom, 
DCT- dual carbapenem therapy, experimental group received DCT treatment, control group 
received monotherapy, p<0.05 is significant, De pascale et al.,[18] Gutierrez-Gutierrez et al.,[20] 
Onal et al.[22]
Figure 4: Overall mortality rates in CPKP infected patients treated with DCT in comparison to 
patients treated with alternate antibiotic combinations. Data shown are number of deaths 
(events) and total number in group (total), data shown are odds ratio and 95% CI, events refer 
to mortality, CI- confidence interval, df- degrees of freedom, DCT-dual carbapenem therapy, 
experimental group received DCT treatment, control group received alternate antibiotic 
combinations, p<0.05 is significant. Tumbarello et al.,[21] Giannella et al.,[23] and Venugopalan 
et al.[24]
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Mortality rates in patients treated with DCT in 
comparison to standard antibiotic regimes 14 days 
post-initiation of treatment
The studies included in the analysis displayed low 
heterogeneity (I² = 0%). Patients receiving DCT 
had a lower 14 days mortality rate in comparison 
to patients receiving standard antibiotic treatment 
(OR = 0.79, 95% CI [0.53, 1.16]). However, the 
overall effect of DCT on 14 days mortality rate was 
non-significant (Z = 1.20 [P = 0.23]), as illustrated in 
Figure 6.
Mortality rates in patients treated with DCT in 
comparison to standard antibiotic regimes 28–30 
days post-initiation of treatment
The studies included in the analysis displayed low 
heterogeneity (I² = 0%). Patients receiving DCT had 
a lower 28–30 days mortality rate in comparison to 
patients receiving standard antibiotic combinations 
(OR = 0.59, 95% CI [0.38, 0.94]). This difference 
in 28–30 days mortality rate between patients 
receiving DCT and patients receiving standard 
antibiotic treatment was significant (Z = 2.24 
[P = 0.02]), as illustrated in Figure 7.
Mortality rates in patients treated with DCT in 
comparison to standard antibiotic regimes 60–90 
days post-initiation of treatment
The studies included in the analysis displayed low 
heterogeneity (I² = 0%). Patients receiving DCT had 
a lower 60–90 days mortality rate in comparison 
to patients receiving standard antibiotic 
treatment (OR = 0.67, 95% CI [0.35, 1.29]). However, 
the overall effect of DCT on 60–90 days mortality 
rate was non-significant (Z = 1.20 [P = 0.23]), as 
illustrated in Figure 8.
Figure 5: 14 days mortality rate in patients treated with DCT in comparison to patients treated 
with combination therapy. Data shown are number of deaths (events) and total number 
within group (total), data shown are odds ratio and 95% CI, CI- confidence interval, df- degrees 
of freedom, DCT- dual carbapenem therapy, experimental group received DCT, control group 
received combination antibiotic regimens, Gianella et al.,[23] Tumbarello et al.[21]
Figure 6: 14 days mortality rate in CPKP infected patients treated with DCT in comparison 
to patients treated with standard antibiotic regimens. Data shown are number of deaths 
(events) and total number in group (total), data shown are odds ratio and 95% CI, events 
refer to mortality, CI- confidence interval, df- degrees of freedom, SAT- standard antibiotic 
therapy, DCT- dual carbapenem therapy, experimental group received DCT treatment, control 
group received standard antibiotic regimens, p<0.05 is significant. Tumbarrello et al.,[21] 
Tumbarrello,[21] Gianella et al.[23]
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Microbiological cure rates in patients treated 
with DCT in comparison to standard antibiotic 
regimes
The studies included in this analysis displayed low 
heterogeneity (I² = 0%). Patients receiving DCT had 
a higher microbiological cure rate in comparison 
to patients receiving standard antibiotic regimes 
(OR = 2.14, 95% CI [1.24, 3.71]). This difference in 
microbiological cure rate between patients receiving 
DCT and those receiving standard antibiotic 
regimens was significant (Z = 2.71, [P = 0.007]), as 
illustrated in Figure 9.
Publication bias
To investigate potential publication bias funnel 
plots were produced of the included studies. The 
funnel plots display symmetry, suggesting that 
publication bias is not an issue in these analyses, as 
demonstrated by Figures 10 and 11.
The funnel plot produced for the studies included 
in the analysis of microbiological cure rate, displays 
asymmetry, suggesting the possible influence of 
publication bias, as demonstrated in Figure 12.
Discussion
Impact of the results of the present analysis
The majority of studies included in the analysis 
displayed homogeneity. The I² statistics were 
low (<50%), or moderate (66%) as in the case of 
one analysis, suggesting there is very little inter-
study variation in the results. Although the test 
of heterogeneity was not statistically significant, 
a random effects model was still selected for this 
analysis. Although the test of heterogeneity did not 
reach statistical significance, this may have been 
due to low power, the observed effect sizes may 
still vary across a range in studies with a great deal 
Figure 7: 28-30 days mortality rate in CPKP infected patients treated with DCT in comparison 
to patients treated with standard antibiotic regimens. Data shown are number of deaths 
(events) and total number in group (total), data shown are odds ratio and 95% CI, events refer 
to mortality, CI-confidence interval, df- degrees of freedom, SAT-standard antibiotic therapy, 
DCT-dual carbapenem therapy, experimental group received DCT treatment, control group 
received standard antibiotic regimens, p<0.05 is significant. De Pascale et al.,[18] Gutierrez-
Gutierrez et al.,[20] Onal et al.,[22] Venugopalan et al.[24]
Figure 8: 60-90 days mortality rate in CPKP infected patients treated with DCT in comparison 
to patients treated with standard antibiotic regimens. Data shown are number of deaths 
(events) and total number in group (total), data shown are odds ratio and 95% CI, events 
refer to mortality, CI-confidence interval, df- degrees of freedom, SAT- standard antibiotic 
therapy, DCT-dual carbapenem therapy, experimental group received DCT treatment, control 
group received standard antibiotic regimens, p<0.05 is significant. De Pascale et al.,[18] Cancelli 
et al.[19]
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or error, for example. The ORs with respect to each 
study were subject to variation (OR = 0.11–6.25), 
and for this reason a random effects model was 
selected. An additional benefit of utilizing a random 
effects model is that this model allows greater 
generalizability of the results, beyond the scope 
of the studies included in the analysis allowing 
the conclusions drawn from this analysis to be 
generalized into clinical practice.
The funnel plots produced for the studies included 
in the analysis of microbiological cure rate displayed 
asymmetry, suggesting the influence of publication 
bias in this analysis. Asymmetry may be ascribed 
to poor methodological study design, typically a 
feature of studies with a small sample size, and 
resulting in an overestimation of the treatment 
effect.[25] However, all the studies included in the 
present analysis have relatively large sample sizes, 
suggesting another factor as the causative agent 
for the asymmetry. Heterogeneity in the studies 
is another causative factor of asymmetry in funnel 
plots, similarly; however, the included studies were 
determined to be homogenous, thus heterogeneity 
is an unlikely cause of the asymmetry. Funnel 
plots become unreliable methods of investigating 
publication bias when the number of studies is 
Figure 9: Microbiological cure rate in CPKP infected patients treated with DCT and those 
treated with standard antibiotic regimes. Data shown are number of cases achieving 
microbiological cure (events) and total number in group (total), data shown are odds ratio and 
95% CI, events refer to microbiological cure, CI- confidence interval, df- degrees of freedom, 
SAT- standard antibiotic therapy, DCT- dual carbapenem therapy, experimental group received 
DCT treatment, control group received standard antibiotic regimes, p<0.05 is significant. 
Cancelli et al.,[19] De Pascale et al.,[18] Onal et al.,[22] Venugopalan et al.[24]
Figure 10: Publication bias of studies included 
in the analysis of overall mortality rates in 
patients treated with DCT in comparison to 
patients treated with monotherapy. OR-odds 
ratio, SE(log[OR])- standard error (log[OR]), 
De Pascale et al.[18], Cancelli et al.[19], 
Gutierrez-Gutierrez et al. (20), Tumbarello 
et al.[21], Onal et al.[22]
Figure 11: Publication bias in the studies 
included in the analysis of overall mortality 
rates in patients treated with DCT in 
comparison to patients treated with 
alternate antibiotic combinations. OR- odds 
ratio, SE(log[OR])- standard error (log[OR]), 
Tumbarello et al.[21], Giannella et al.[23], and 
Venugopalan et al.[24]
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small, as is the case with the present analysis, 
thus uncertainties remain as to the true effect of 
publication bias in the analysis of the microbiological 
cure rate.
Evidencing the symbiotic and bactericidal effects of 
DCT, patients treated with DCT had a significantly 
higher microbiological cure rate in comparison to 
the microbiological cure rate in patients treated 
with standard antibiotic regimens. Carbapenem 
antibiotics are beta-lactamase inhibitors, exerting 
their bactericidal effects through binding of 
penicillin-binding-proteins present on the bacterial 
cell wall, inhibiting the synthesis of peptidoglycan, 
an essential component of the cell wall in many 
bacterial species including K. pneumoniae, resulting 
in a weakening, and subsequent lysis of the 
bacterial cell due to osmotic pressure, and thus 
cell death.[26,27] The synergistic action of the dual 
carbapenem combination explains the significantly 
greater microbiological cure rate seen in patients to 
whom DCT was administered.
DCT significantly lowered the 28–30 days 
mortality rate in patients in comparison to 
standard antibiotic therapies, this effect may be 
explained by the action of ertapenem and the 
second carbapenem acting synergistically. The 
carbapenemase enzyme produced by CPKP has 
a greater affinity for ertapenem in comparison to 
other carbapenem antibiotics, as such ertapenem 
is administered first, and due to its high affinity for 
the carbapenemase enzyme, it binds with ease to 
the enzyme, resulting in a depletion of the enzyme, 
sufficient time for this reaction to occur elapses 
before the second carbapenem, meropenem or 
doripenem, is administered. Due to depletion of 
the carbapenemase enzyme in the reaction with 
ertapenem, higher concentrations of the second 
carbapenem are established in the environment 
surrounding the bacteria which would otherwise 
be concentrated with the carbapenemase 
enzyme. Alternatively, ertapenem may act as 
a suicide inhibitor. Ertapenem may bind to the 
carbapenemase enzyme and be hydrolyzed. The 
second carbapenem is then administered, again 
allowing sufficient time for the reaction between 
ertapenem and the carabapenemase enzyme to 
occur. The carbapenemase enzyme is bound to 
ertapenem, thus there is a lower concentration 
of enzyme available to hydrolyze the second 
carbapenem; consequently, this carbapenem can 
exert its bactericidal effect.[2,6,26]
DCT did not significantly lower the 60–90 days 
mortality rate in patients diagnosed with CPKP 
infections, in comparison to standard antibiotic 
treatments. The failure of DCT to sustain 
effectiveness at the 60–90 days time point may be 
attributed to unmeasured confounders occurring so 
long post-treatment. The fact that all the included 
studies were retrospective observational studies, 
and therefore have the possibility to be influenced 
by confounding variables, such as underlying 
comorbidities, strengthens this hypothesis.
DCT also had no significant effect on the 14 days 
mortality rate in comparison to standard antibiotic 
treatments. This is suggestive of DCT’s need for 
accumulation of efficacy over a prolonged course 
of therapy to have a significant effect. This theory 
is supported by the findings of Wiskirchen et al.[28] 
Wiskirchen et al. reported DCT demonstrated 
significantly enhanced efficacy when compared 
to monotherpay in the treatment of murine CPKP 
infections, but only 72 h post-infection, not at prior 
time points. Taken together, this suggests that DCT 
may take time to have a significant effect, 14–28 
days, and, additionally, that while DCT may be 
initially effective in treating CPKP infections, such 
effectiveness is not maintained, up to 60 or 90 days 
follow-up.
DCT failed to significantly lower the overall mortality 
rate in patients diagnosed with CPKP infections in 
comparison to patients treated with monotherapy 
antibiotic regimes.
Figure 12: Publication bias in the studies 
included in the analysis of microbiological 
cure rate in patients treated with DCT 
in comparison to patients treated with 
standard antibiotic therapy. OR-odds ratio, SE 
(log[OR])- standard error(log[OR]), Cancelli 
et al.[19], De Pascale et al.[18], Onal et al.[22], 
Venugopalan et al.[24]
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Similarly, DCT failed to significantly lower the overall 
mortality rate in patients diagnosed with CPKP 
infections in comparison to alternative antibiotic 
combination regimes. One possible explanation for 
the failure of DCT to significantly lower the overall 
mortality rate in patients may be the uncertainty 
surrounding DCT’s mechanism of action. Varying 
hypothesis exists to explain the mechanisms 
underpinning the possible effectiveness of DCT; 
the establishment of higher concentrations of the 
carbapenem antibiotic in the microenvironment 
of the bacteria which would otherwise be 
concentrated with carbapenemase enzyme may 
play a role, alternately the lower concentration 
of enzyme available to hydrolyze the carbapenem 
antibiotic may be responsible. Failure to elucidate 
these mechanisms prevents accurate predictions 
regarding the effectiveness of a DCT regimen in the 
treatment of infections due to CPKP.
Nonetheless, DCT did significantly lower the 28–30 
days mortality rate, in particular, when compared to 
monotherapy antibiotic regimens. This effect may 
be due to the synergism of the two carbapenems 
antibiotics, which is an advantage in comparison 
to monotherapy antibiotic regimens. These results 
are in line with those obtained by Oliva et al., who 
determined the combination of ertapenem and 
meropenem to be synergistic and bactericidal in 
activity against K. pneumonia.[29]
In contrast, DCT failed to significantly lower the 14 
days mortality rate in patients in comparison to 
patients treated with other antibiotic combination 
regimens. This suggests that whilst DCT may 
be significantly more effective in treating CPKP 
infection than monotherapy regimens, DCT is not 
more effective than other antibiotic combinations. 
Opposingly, the causative factor for these results 
may be the accumulation of efficacy over a 
prolonged time period required to yield a significant 
effect within a DCT regimen. These results support 
the finding that DCT failed to significantly lower 
the 14 days mortality rate when compared to 
standard antibiotic regimens, which included both 
monotherapy and combination regimens. Thus, 
these results strengthen the hypothesis that DCT 
has a time dependent effect on mortality rates.
Such findings indicate that DCT may have a time-
dependent effect on mortality rates. Evidencing 
that while DCT may be initially effective at lowering 
the mortality rate in patients, such a response is 
not maintained in the long term. However, failure 
to maintain effectiveness may be less to do with 
an inherent flaw in DCT but rather due to the 
influence of confounding variables not controlled 
for in the included studies. Thus, there is a need for 
randomized controlled trials to determine if DCT’s 
effectiveness can be sustained when confounding 
variables are controlled for.
The findings presented here indicate that, up to 
2 weeks post-initiation of treatment, there was 
no significant difference in the mortality rates of 
patients receiving DCT in comparison to patients 
receiving SAT. Interestingly, however, 28–30 days 
post-initiation of antibiotic treatment, there was 
a significantly lower mortality rate in the cohort 
of patients to whom DCT was administered in 
comparison to those receiving SAT. However, 60–90 
days post-initiation of treatment, this significant 
difference was absent, and no significant difference 
existed in the mortality rates in the cohort of 
patients who had been receiving SAT, compared to 
that in the cohort of patients who had received DCT.
Conclusion
DCT significantly improved the microbiological cure 
rate in CPKP infected patients in comparison to standard 
antibiotic treatments. DCT failed to significantly 
lower the overall mortality rate in comparison to the 
overall mortality rates in patients treated with either 
monotherapy or alternate combination therapies. 
However, when stratified by time post initiation 
of treatment, DCT significantly lowered the 28–30 
days mortality rate in patients in comparison to the 
28–30 days mortality rate in patients treated with 
monotherapy. Contrastingly, when stratified according 
to time post-initiation of treatment, DCT still had 
no significant effect on the 14 days mortality rate in 
comparison to the 14 days mortality rate in patients 
treated with alternate combination therapies. DCT did 
not significantly lower the 14 days mortality rate in 
comparison to standard antibiotic regimens. DCT did, 
however, significantly lower the 28–30 days mortality 
rate in patients in comparison to standard antibiotic 
regimens. DCT did not significantly lower the 60–
90 days mortality rate in comparison to standard 
antibiotic regimens. These results indicate a time 
dependent response in the effectiveness of a DCT 
regimen. Overall, DCT demonstrated efficacy in the 
treatment of CPKP infection, significantly lowering the 
28–30 days mortality rate and significantly improving 
the microbiological cure rate, in comparison to 
standard antibiotic treatments, and thus may be a 
valid therapeutic option for the treatment of CPKP 
infections.
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